Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: FLARE

EU Approves Tofacitinib Citrate for 2 Pediatric Conditions

Michele B. Kaufman, PharmD, BCGP  |  September 8, 2021

The European Commission approved tofacitinib citrate to treat two pediatric conditions, as well as a prolonged-release version of the medication designed to treat adults with active PsA.

Filed under:ConditionsDrug UpdatesPediatric ConditionsPsoriatic Arthritis Tagged with:drug approvalsEuropeEuropean Unionjuvenile idiopathic arthritis (JIA)juvenile PsAPediatricPediatric RheumatologyPsAPsoriatic Arthritistofacitinib citrate

ACR Guidance on Tocilizumab Allocation During Shortage

From the College  |  September 1, 2021

In June, the U.S. Food & Drug Administration (FDA) issued an emergency use authorization (EUA) for tocilizumab (Actemra) for treatment of hospitalized COVID-19 adults and children who are receiving systemic corticosteroids and supplemental oxygen. Since this announcement, the tocilizumab manufacturer, Genentech, has not been able to produce enough product to meet the higher demand. The…

Filed under:Drug UpdatesLegislation & Advocacy Tagged with:COVID-19Drug shortagetocilizumab

Updates in Pediatric Lupus: Experts Discuss Advances in Lupus Nephritis Treatments, Monogenic Lupus & More

Elizabeth Sloan, MD  |  August 31, 2021

PRSYM—At the 2021 Pediatric Rheumatology Symposium (PRSYM), a session on lupus provided a robust discussion of recent advances in lupus treatments and genetic discoveries in pediatric rheumatology. Lupus Nephritis The first speaker was Shaun Jackson, MD, PhD, a pediatric nephrologist and rheumatologist and associate professor at Seattle Children’s. His presentation focused on state-of-the-art treatments in…

Filed under:ConditionsPediatric ConditionsSystemic Lupus Erythematosus Tagged with:Lupus nephritisPediatricPediatric RheumatologyPRSYMsystemic lupus erythematosus (SLE)

2-Year Extension Study Supports Voclosporin to Treat Patients with Lupus Nephritis

Lara C. Pullen, PhD  |  August 23, 2021

Research has shown voclosporin in combination with MMF and low-dose steroids benefits patients with lupus nephritis, significantly increasing the speed of remission. New data from an ongoing extension study demonstrate a positive risk/benefit profile.

Filed under:ConditionsDrug UpdatesSystemic Lupus Erythematosus Tagged with:kidneyLupus nephritisvoclosporin

COVID-19 Vaccine Efficacy & Safety Discussed at Town Hall

Ruth Jessen Hickman, MD  |  August 20, 2021

At a recent ACR town hall, panelists described immune responses and side effects of COVID-19 vaccination in patients with rheumatic disease, along with ways to leverage monoclonal antibody treatments, especially in light of virus variants.

Filed under:American College of Rheumatology Tagged with:COVID-19immunosuppressionvaccination

Healthcare Extenders Can Reduce Physician Burden & Improve Patient Access & Care

Kimberly Steinbarger, PT, MHS, DHSc, & Saba Mohiuddin, PharmD, BCACP  |  August 11, 2021

In the early 1900s, the treatment for rheumatic and musculoskeletal disease (RMD) was primarily targeted at symptomatic relief and included analgesics, physical therapy, splinting and bed rest. With the discovery of methotrexate and its impact on rheumatoid arthritis (RA) management, a much-needed evolution of medications targeting disease activity began. Over the past 30 years, several…

Filed under:Interprofessional PerspectiveWorkforce Tagged with:Advanced Practice CliniciansAssociation of Rheumatology Professionals (ARP)dietitiannurse practitioneroccupational therapistspharmacistphysical therapistphysician assistantssocial worker

Dusan Petkovic / shutterstock.com

COVID-19 Vaccination in Patients with Rheumatic Disease

Ruth Jessen Hickman, MD  |  August 11, 2021

With a large percentage of the U.S. population unsure whether they will get vaccinated against COVID-19, rheumatology patients remain vulnerable. On May 13, the ACR hosted a virtual town hall highlighting ways rheuma­tology providers might effectively approach their patients who have not yet decided to get a COVID-19 vaccine. Get the Slow Yes At the…

Filed under:ConditionsPatient Perspective Tagged with:COVID-19patient communicationvaccinationvaccine hesitancy

Sci Writers / shutterstock.com

FDA’s Arthritis Advisory Committee Narrowly Endorses Avacopan Approval

Ruth Jessen Hickman, MD  |  August 11, 2021

On May 6, the U.S. Food & Drug Administration’s (FDA’s) Arthritis Advisory Committee narrowly voted in support of avacopan, a C5a receptor inhibitor, for the treatment of adult patients with anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis. Although the panelists were excited about the possibility of a steroid-sparing therapy, some raised questions about whether results from…

Filed under:ConditionsDrug UpdatesVasculitis Tagged with:ANCA-Associated VasculitisavacopanGlucocorticoids

Colchicine: An Ancient Drug with Modern Uses

Ibrahem Salloum, MD, & Deepan S. Dalal, MD, MPH  |  August 11, 2021

Discovered more than 3,000 years ago, colchicine is one of the oldest drugs still in use today. Like most old remedies, colchicine is a chemical substance found in many plants, most notably in colchicum autumnale, known as wild saffron or autumn crocus. It was mentioned in the oldest Egyptian medical text, Ebers Papyrus (circa 1550…

Filed under:ConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:anti-inflammatoryColchicinedrug treatmentGoutinflammation

Will an App to Monitor Patient Outcomes Improve RA Disease Activity?

Arthritis & Rheumatology  |  July 26, 2021

Lee et al. examined the use of a smartphone application to monitor longitudinal electronic patient-reported outcomes on satisfaction and disease activity in patients with RA.

Filed under:AppsConditionsResearch RheumRheumatoid ArthritisTechnologyTechnology Tagged with:Arthritis & Rheumatologypatient outcomesResearchRheumatoid Arthritis (RA)smartphoneSmartphone appTechnology

  • « Previous Page
  • 1
  • …
  • 23
  • 24
  • 25
  • 26
  • 27
  • …
  • 68
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences